Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice - PubMed (original) (raw)
. 2000 Mar 1;9(4):503-13.
doi: 10.1093/hmg/9.4.503.
J K White, C A Gutekunst, V Vrbanac, M Weaver, X J Li, S H Li, H Yi, J P Vonsattel, J F Gusella, S Hersch, W Auerbach, A L Joyner, M E MacDonald
Affiliations
- PMID: 10699173
- DOI: 10.1093/hmg/9.4.503
Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
V C Wheeler et al. Hum Mol Genet. 2000.
Abstract
Huntington's disease (HD) is caused by an expanded N-terminal glutamine tract that endows huntingtin with a striatal-selective structural property ultimately toxic to medium spiny neurons. In precise genetic models of juvenile HD, HdhQ92 and HdhQ111 knock-in mice, long polyglutamine segments change huntingtin's physical properties, producing HD-like in vivo correlates in the striatum, including nuclear localization of a version of the full-length protein predominant in medium spiny neurons, and subsequent formation of N-terminal inclusions and insoluble aggregate. These changes show glutamine length dependence and dominant inheritance with recruitment of wild-type protein, critical features of the altered HD property that strongly implicate them in the HD disease process and that suggest alternative pathogenic scenarios: the effect of the glutamine tract may act by altering interaction with a critical cellular constituent or by depleting a form of huntingtin essential to medium spiny striatal neurons.
Similar articles
- Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice.
Wheeler VC, Gutekunst CA, Vrbanac V, Lebel LA, Schilling G, Hersch S, Friedlander RM, Gusella JF, Vonsattel JP, Borchelt DR, MacDonald ME. Wheeler VC, et al. Hum Mol Genet. 2002 Mar 15;11(6):633-40. doi: 10.1093/hmg/11.6.633. Hum Mol Genet. 2002. PMID: 11912178 - Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA. Cooper JK, et al. Hum Mol Genet. 1998 May;7(5):783-90. doi: 10.1093/hmg/7.5.783. Hum Mol Genet. 1998. PMID: 9536081 - Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. Kuhn A, et al. Hum Mol Genet. 2007 Aug 1;16(15):1845-61. doi: 10.1093/hmg/ddm133. Epub 2007 May 21. Hum Mol Genet. 2007. PMID: 17519223 - The selective vulnerability of nerve cells in Huntington's disease.
Sieradzan KA, Mann DM. Sieradzan KA, et al. Neuropathol Appl Neurobiol. 2001 Feb;27(1):1-21. doi: 10.1046/j.0305-1846.2001.00299.x. Neuropathol Appl Neurobiol. 2001. PMID: 11298997 Review. - Polyglutamine pathogenesis.
Ross CA, Wood JD, Schilling G, Peters MF, Nucifora FC Jr, Cooper JK, Sharp AH, Margolis RL, Borchelt DR. Ross CA, et al. Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1005-11. doi: 10.1098/rstb.1999.0452. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434299 Free PMC article. Review.
Cited by
- Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review.
Zhao T, Hong Y, Li XJ, Li SH. Zhao T, et al. Front Mol Neurosci. 2016 Apr 21;9:27. doi: 10.3389/fnmol.2016.00027. eCollection 2016. Front Mol Neurosci. 2016. PMID: 27147961 Free PMC article. Review. - A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers.
Kelp A, Koeppen AH, Petrasch-Parwez E, Calaminus C, Bauer C, Portal E, Yu-Taeger L, Pichler B, Bauer P, Riess O, Nguyen HP. Kelp A, et al. J Neurosci. 2013 May 22;33(21):9068-81. doi: 10.1523/JNEUROSCI.5622-12.2013. J Neurosci. 2013. PMID: 23699518 Free PMC article. - Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F. Pineda JR, et al. Mol Brain. 2009 Oct 27;2:33. doi: 10.1186/1756-6606-2-33. Mol Brain. 2009. PMID: 19860865 Free PMC article. - Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease.
Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. Landles C, et al. J Biol Chem. 2010 Mar 19;285(12):8808-23. doi: 10.1074/jbc.M109.075028. Epub 2010 Jan 19. J Biol Chem. 2010. PMID: 20086007 Free PMC article. - The roles of proteolysis and nuclear localisation in the toxicity of the polyglutamine diseases. A review.
Walsh R, Storey E, Stefani D, Kelly L, Turnbull V. Walsh R, et al. Neurotox Res. 2005;7(1-2):43-57. doi: 10.1007/BF03033775. Neurotox Res. 2005. PMID: 15639797 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials